NCT Number |
Title |
Conditions |
Interventions |
Sponsor/Collaborators |
Phases |
NCT03304639 |
Pembrolizumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Merkel Cell Cancer |
Stage III Merkel Cell Carcinoma AJCC v7|Stage IIIA Merkel Cell Carcinoma AJCC v7|Stage IIIB Merkel Cell Carcinoma AJCC v7|Stage IV Merkel Cell Carcinoma AJCC v7 |
Biological: Pembrolizumab|Radiation: Stereotactic Body Radiation Therapy |
National Cancer Institute (NCI) |
Phase 2 |
NCT03302897 |
Phase 1 LEP-F1 + GLA-SE Vaccine Trial in Healthy Adult Volunteers |
Leprosy |
Biological: LEP-F1 + GLA-SE |
IDRI|American Leprosy Missions |
Phase 1 |
NCT03302247 |
Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy |
Non Small Cell Lung Cancer Stage IIIB |
Biological: Nivolumab|Drug: Nivolumab+Gemcitabine |
Fox Chase Cancer Center |
Phase 2 |
NCT03301090 |
A Safety, Tolerability, Pharmacokinetics and Immunogenicity Trial of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051 |
Corona Virus Infection |
Other: Placebo|Biological: REGN3048|Biological: REGN3051 |
National Institute of Allergy and Infectious Diseases (NIAID) |
Phase 1 |
NCT03300843 |
Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer |
Melanoma|Gastrointestinal Cancer|Breast Cancer|Ovarian Cancer|Pancreatic Cancer |
Biological: Peptide loaded dendritic cell vaccine |
National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Phase 2 |
NCT03299946 |
Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC) |
Locally Advanced Hepatocellular Carcinoma |
Drug: Cabozantinib|Drug: Nivolumab |
Sidney Kimmel Comprehensive Cancer Center|Exelixis|Bristol-Myers Squibb |
Phase 1 |
NCT03299088 |
Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations |
KRAS Gene Mutation|Metastatic Non-Squamous Non-Small Cell Lung Carcinoma|Recurrent Non-Squamous Non-Small Cell Lung Carcinoma|Stage IV Non-Small Cell Lung Cancer AJCC v7 |
Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab|Drug: Trametinib |
University of California, Davis|Merck Sharp & Dohme Corp.|Novartis|National Cancer Institute (NCI) |
Phase 1 |
NCT03298464 |
Study of NGM313 in Obese Participants |
Obese |
Biological: NGM313|Drug: Pioglitazone |
NGM Biopharmaceuticals, Inc |
Phase 1 |
NCT03298048 |
Dose Ranging Study of the Safety and Efficacy of Orally Administered Lyophilized Fecal Microbiota Product (PRIM-DJ2727) for the Treatment of Recurrent Clostridium Difficile Infection (CDI) |
Recurrent C. Difficile Infection |
Biological: Low fecal microbiota dose|Biological: Mid fecal microbiota dose|Biological: High fecal microbiota dose |
The University of Texas Health Science Center, Houston |
Phase 2 |
NCT03295227 |
Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma |
Thymoma|Thymic Cancer |
Drug: Pembrolizumab |
M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp. |
Phase 1 |
NCT03300817 |
MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer |
Current Smoker|Former Smoker |
Other: Laboratory Biomarker Analysis|Biological: MUC1 Peptide-Poly-ICLC Vaccine |
National Cancer Institute (NCI) |
Phase 1 |
NCT03300544 |
Talimogene Laherparepvec, Capecitabine, and Chemoradiation Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer |
Rectal Adenocarcinoma|Stage III Rectal Cancer AJCC v7|Stage IIIA Rectal Cancer AJCC v7|Stage IIIB Rectal Cancer AJCC v7|Stage IIIC Rectal Cancer AJCC v7|Stage IV Rectal Cancer AJCC v7|Stage IVA Rectal Cancer AJCC v7|Stage IVB Rectal Cancer AJCC v7 |
Drug: Capecitabine|Drug: Fluorouracil|Other: Laboratory Biomarker Analysis|Drug: Oxaliplatin|Radiation: Radiation Therapy|Biological: Talimogene Laherparepvec |
National Cancer Institute (NCI) |
Phase 1 |
NCT03300050 |
Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine |
Influenza|Vaccine |
Biological: cH8/1N1 LAIV|Biological: cH5/1N1 IIV + adjuvant|Biological: cH5/1N1 IIV|Biological: cH8/1N1 IIV + adjuvant|Biological: Normal saline|Biological: Phosphate buffered saline |
PATH|Icahn School of Medicine at Mount Sinai|Children's Hospital Medical Center, Cincinnati|Duke University|The EMMES Corporation|GlaxoSmithKline |
Phase 1 |
NCT03298399 |
Mesenchymal Stromal Cells for Haplo Hematopoietic Cell Transplantation for Sickle Cell Disease |
Sickle Cell Disease |
Biological: Autologous MSCs |
Emory University|National Heart, Lung, and Blood Institute (NHLBI) |
Phase 1 |
NCT03293498 |
Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu) |
Influenza |
Biological: NanoFlu|Biological: Fluzone HD - Day 0|Biological: Fluzone HD - Day 21|Other: Saline - Day 21 |
Novavax |
Phase 1
Phase 2 |
NCT03304080 |
Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in Her-positive, Her2-positive Metastatic Breast |
Breast Neoplasms|Breast Diseases |
Drug: Anastrozole|Drug: Palbociclib|Drug: Trastuzumab|Drug: Pertuzumab |
Icahn School of Medicine at Mount Sinai|Herbert Irving Comprehensive Cancer Center|Weill Medical College of Cornell University|New York University Langone Medical Center |
Phase 1
Phase 2 |
NCT03302234 |
Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer (MK-3475-598/KEYNOTE-598) |
Carcinoma, Non-Small-Cell Lung |
Biological: pembrolizumab|Biological: ipilimumab|Other: placebo for ipilimumab |
Merck Sharp & Dohme Corp. |
Phase 3 |
NCT03301220 |
A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma |
Smoldering Multiple Myeloma |
Drug: Daratumumab SC |
Janssen Research & Development, LLC |
Phase 3 |
NCT03301051 |
Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Adults |
Virus Diseases|RNA Virus Infections|Respiratory Tract Diseases|Respiratory Tract Infections |
Biological: Quadrivalent VLP Vaccine|Biological: Placebo |
Medicago |
Phase 3 |
NCT03298451 |
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma |
Hepatocellular Carcinoma |
Drug: Durvalumab|Drug: Tremelimumab (Regimen 1)|Drug: Tremelimumab (Regimen 2)|Drug: Sorafenib|Drug: Durvalumab (Regimen 1)|Drug: Durvalumab (Regimen 2) |
AstraZeneca |
Phase 3 |
NCT03298061 |
Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921 |
Churg-Strauss Syndrome |
Drug: Mepolizumab |
GlaxoSmithKline |
Phase 3 |
NCT03298867 |
Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study |
Thyroid Eye Disease|Graves' Orbitopathy |
Biological: Teprotumumab|Other: Placebo |
Horizon Pharma USA, Inc. |
Phase 3 |
NCT03301896 |
Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies |
Solid Tumors |
Drug: LHC165|Biological: PDR001 |
Novartis Pharmaceuticals|Novartis |
Phase 1 |
NCT03307603 |
Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer |
Metastatic Colorectal Cancer |
Radiation: yttrium-90 radioembolization|Drug: Phase Ib - nivolumab|Drug: Phase II - nivolumab |
Case Comprehensive Cancer Center |
Phase 1
Phase 2 |
NCT03305445 |
Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL |
Relapsed Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma |
Drug: Ipilimumab|Drug: Nivolumab |
Icahn School of Medicine at Mount Sinai|Bristol-Myers Squibb |
Phase 1
Phase 2 |
NCT03311126 |
Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma |
Mantle Cell Lymphoma|Non-hodgkin Lymphoma|Non Hodgkin Lymphoma |
Drug: Bendamustine|Drug: Obinutuzumab |
University of Wisconsin, Madison|Genentech, Inc.|National Cancer Institute (NCI) |
Phase 2 |
NCT03310567 |
A Study of Pembrolizumab in Combination With Epacadostat in Women With Recurrent/Metastatic Endometrial Carcinoma |
Recurrent/ Metastatic Endometrial Carcinoma |
Drug: Epacadostat + pembrolizumab |
Fox Chase Cancer Center |
Phase 2 |
NCT03310021 |
A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects |
Bleeding |
Biological: Andexanet alfa|Drug: Apixaban|Drug: Rivaroxaban|Drug: Edoxaban|Drug: Placebo |
Portola Pharmaceuticals |
Phase 2 |
NCT03308942 |
Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination With PD-1 Inhibitor in Patients With Non-Small Cell Lung Cancer |
Lung Neoplasms |
Drug: Niraparib|Biological: PD-1 Inhibitor |
Tesaro, Inc.|INC Research|Covance|Myriad Genetics, Inc.|NeoGenomics Laboratories|DrugDev|Resolution Bioscience |
Phase 2 |
NCT03307915 |
A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment |
Human Immunodeficiency Virus |
Biological: Ad26.Mos4.HIV|Biological: MVA-Mosaic|Biological: Clade C gp140 + Mosaic gp140|Drug: Placebo |
Janssen Vaccines & Prevention B.V.|Beth Israel Deaconess Medical Center|Ragon Institute|Military HIV Research Program |
Phase 1 |
NCT03307616 |
Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma |
Systemic Connective Tissue Disorders |
Drug: Nivolumab|Drug: Ipilimumab|Radiation: Radiation Therapy |
M.D. Anderson Cancer Center|Bristol-Myers Squibb |
Phase 2 |
NCT03309111 |
Study of GBR 1342 in Subjects With Previously Treated Multiple Myeloma |
Multiple Myeloma |
Biological: GBR 1342 |
Glenmark Pharmaceuticals S.A. |
Phase 1 |
NCT03308968 |
An Efficacy and Safety Study of Fremanezumab in Adults With Migraine |
Migraine Prophylaxis |
Drug: Fremanezumab|Drug: Placebo |
Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries |
Phase 3 |
NCT03306277 |
Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 |
SMA - Spinal Muscular Atrophy|Gene Therapy |
Biological: AVXS-101 |
AveXis, Inc. |
Phase 3 |